Birmingham, ALNCT06599697Now EnrollingIRB Ready

Necrotizing Myopathy Clinical Trial in Birmingham, AL

Access cutting-edge necrotizing myopathy treatment through this clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.

Sponsored by University of Alabama at Birmingham

Quick Self-Assessment

See if you qualify for this Birmingham location

Preparing your pre-screening questions…

Expert Care in Birmingham

Access necrotizing myopathy specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related necrotizing myopathy treatment provided free

Apply for This Birmingham Location

Check if you qualify for this necrotizing myopathy clinical trial in Birmingham, AL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Birmingham

    Convenient for AL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Birmingham site if eligible
  4. 4Begin participation

About This Necrotizing Myopathy Study in Birmingham

This is a randomized, placebo-controlled, double blinded phase 2 exploratory clinical trial of intravenously administered pooled human immunoglobulin (IVIG) in anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) immune mediated necrotizing myopathy (IMNM). Planned enrollment is 12 individuals with active anti-HMGCR IMNM meeting inclusion and exclusion criteria. Assuming 20% drop-out, the investigators anticipate 10 participants will complete all study assessments. Enrolled participants will be

Sponsor: University of Alabama at Birmingham

Who Can Participate

Inclusion Criteria

Age \> 16 years
Anti-HMGCR antibody positive
MMT-8 score \< 142 (range 0-160)
Serum CK \> 5x upper limit of normal
Anti-HMGCR IMNM disease duration \< 36 months at screening
No moderate or severe respiratory or swallowing dysfunction due to anti-HMGCR IMNM at screening
No history of dermatomyositis rash

Exclusion Criteria

Oral glucocorticoid (GC) daily dose \> 15mg at screening
Change in oral GC dose \< 2 weeks prior to screening
Prior IVIG treatment for anti-HMGCR IMNM -\>1 oral conventional synthetic DMARD (e.g. methotrexate, mycophenolate mofetil, azathioprine) use at screening
Change in concomitant DMARD dose \< 4 weeks prior to screening
Rituximab \< 6 months prior to screening
Plasma exchange, cyclophosphamide, or biologic immunosuppressive medication \< 3 months prior to screening
Use of statin medication at screening
History of anaphylactic reaction to IVIG
History of angina pectoris, myocardial infarction, transient is

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Birmingham?

Yes, this clinical trial (NCT06599697) has an active research site in Birmingham, AL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Necrotizing Myopathy Treatment Options in Birmingham, AL

If you're searching for necrotizing myopathy treatment options in Birmingham, AL, this clinical trial (NCT06599697) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Birmingham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced necrotizing myopathy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Ready to Join in Birmingham?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Birmingham, AL